Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with
chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second-and third …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

Abstract Purpose of Review Over the past two decades, the introduction of tyrosine kinase
inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four …

In 2020, for the great majority of patients with chronic phase chronic myeloid leukemia
(CML), life expectancy is unaffected by a diagnosis of CML because of the unparalleled …

When imatinib, the first tyrosine kinase inhibitor (TKI) developed for use in chronic
myelogenous leukemia (CML), was approved in 2001, the treatment of this disease was …

Background Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem
cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for …

Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is a neoplastic
hematologic disorder, which is a functionally curable chronic disease via using tyrosine …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Abstract Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of one–two cases per 100,000 adults and accounts for∼ 15 …

Simple Summary This review discusses the optimal selection of BCR-ABL1 tyrosine kinase
inhibitors (TKIs) as the first-line treatment for newly diagnosed chronic myelogenous …